The phase III clinical evaluation of LAAM: I. Comparative epidemiology of mortality in LAAM and methadone.
Two essential points can be made: 1. Mortality  experience in the LAAM Phase II trial follows closely the experience of methadone maintenance though these data should be considered preliminary. 2. Generally, the influence of time in treatment on the probability of mortality is strong enough to warrant avoiding comparisons between mortality rates where this parameter is not controlled.
D002986:Clinical Trials as Topic; D006556:Heroin Dependence / Q000188:drug therapy* / Q000534:rehabilitation; D006801:Humans; D008691:Methadone / Q000031:analogs & derivatives* / Q000506:poisoning* / Q000627:therapeutic use; D008692:Methadyl Acetate / Q000506:poisoning* / Q000627:therapeutic use; D009026:Mortality
D008692:Methadyl Acetate; D008691:Methadone